К содержанию
Dr. Tara EinullaevaMedical oncologist

Cancer glossary

Cardiotoxicity: how cancer treatment affects the heart and how it is checked

Cardiotoxicity is heart damage from cancer treatment. Which drugs put the heart at risk, why echocardiograms, ejection fraction and troponin matter, and who needs a cardio-oncologist.

Written and medically reviewed by

Dr. Tara Einullaeva

Medical oncologist, 9 years in practice. Credentials · reviewed 19 October 2026

In short

Cardiotoxicity is damage to the heart or blood vessels from cancer treatment. Most often it means reduced pumping function on anthracyclines (doxorubicin) and anti-HER2 drugs (trastuzumab). Arrhythmias, raised blood pressure and myocarditis on immunotherapy also occur.

How it appears in your report

  • ‘LVEF 62%’ — left ventricular ejection fraction; normal is usually 50–55% or higher.
  • ‘LVEF down from 64% to 51%, GLS −14%’ — signs of worsening function.
  • ‘Troponin I, NT-proBNP’ — blood tests reflecting heart damage and strain.

What it means

Under the 2022 European Society of Cardiology (ESC) guidelines, risk is assessed before treatment starts: heart disease, blood pressure, diabetes, age, previous anthracyclines and chest radiation are taken into account. Everyone has an ECG, and before cardiotoxic treatment an echocardiogram with ejection fraction and, where available, global longitudinal strain (GLS). High-risk patients are referred to a cardio-oncologist.

Cardiotoxicity is considered severe when the ejection fraction falls below 40%, moderate when it drops by 10 points or more to 40–49%, and mild when the fraction is preserved but GLS falls by more than 15% or troponin and NT-proBNP rise. For anthracyclines, risk grows with the cumulative dose: a doxorubicin dose of 250 mg/m² or more counts as higher risk.

Does it affect treatment

Yes. Echocardiogram results can lead to a pause in treatment, heart protection (ACE inhibitors, beta-blockers) or a change of drugs. Regular checks find changes before symptoms appear.

Tell your doctor about breathlessness with ordinary activity, swollen legs, skipped heartbeats or chest pain.

Questions to ask your doctor

  • How often should I have an echocardiogram during treatment?
  • Do I need to see a cardiologist before starting?
  • How should my blood pressure and cholesterol be managed meanwhile?

Sources

  1. 2022 ESC Guidelines on cardio-oncology — European Society of Cardiology
  2. Doxorubicin Hydrochloride — National Cancer Institute
  3. Trastuzumab — National Cancer Institute

FAQ

Related terms

This is reference information and not a substitute for medical advice. Your doctor interprets each value in the context of your whole situation.

Related articles

All blog articles